Mr. Dane Stevens reports

OPTIMI HEALTH LAUNCHES STANDARDIZED MICRODOSE PSILOCYBIN PRODUCTS FOR CLINICAL RESEARCH

Optimi Health Corp. has completed production of two microdose psilocybin finished drug products, formulated at one-milligram and two-milligram dosages. The products are available to qualified, authorized clinical research organizations.

Microdosing refers to taking low, subperceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one day on, two days off) and the Stamets protocol (four days on, three days off), which build in rest days to limit tolerance.

Chief executive officer and co-founder Dane Stevens said: "Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi's capsules instead deliver naturally derived psilocybin at a validated, consistent dose, pairing the natural source many researchers prefer with the accurate dosage that controlled research requires. The one-milligram and two-milligram dosage formats extend Optimi's psilocybin range, which already includes the five-milligram capsule formulation currently prescribed for treatment-resistant depression in Australia."

Optimi produces these products start to finish in-house, cultivating and harvesting the mushrooms, generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, and formulating, encapsulating and packaging the finished product for export to clinical research organizations. Every stage is completed on site Optimi's wholly owned GMP facility in Princeton, B.C., Canada, under its Health Canada drug establishment licence.

Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, supporting both patient access and clinical research.

About Optimi Health Corp.

Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing good-manufacturing-practice-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.

Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program.

We seek Safe Harbor.